Based on a patient's real-life experience


Dymedso is a pioneer in using sound (acoustics) to treat patients with airway clearance challenges resulting from pulmonary disorders and respiratory diseases.

The Company was founded by Louis Plante, a cystic fibrosis (CF) patient, and Yvon Robert, with the sole purpose of improving the quality and care of those struggling to breathe due to mucus filled lungs.

In 2006, following four years of research and in collaboration with a medical team from Sherbrooke University in Quebec, Canada, Dymedso launched the first version of its digitally-controlled acoustic airway clearance device, the Frequencer® 1001. In 2010, Dymedso launched the latest version of the Frequencer® used by hundreds of patients and hospitals around the world today.


The Frequencer® was designed to produce acoustic sound waves at frequencies that cause the lungs to vibrate and change the viscosity and rheology of mucus, making it more liquid and easier to expectorate.

Dymedso first demonstrated that repetitive sound waves at 40Hz is the optimal frequency to reduce the viscosity of mucus in an internal in vitro study conducted in 2004. Peer-reviewed manuscripts published by Cantin et al in 2006 and Schieppati et al in 2017 confirmed the original findings showing the application of the Frequencer® to a simulated thick mucus preparation resulted in a significant acceleration of the flow of the mucin solution.


Dymedso continues to explore ways to improve its product offering, by conducting research to develop products for treatment of an even wider range of patients requiring airway clearance.

The Company is committed to better patient care and health outcomes and is involved in
clinical trials evaluating the use of the Frequencer® in a wide range of patient populations.

Dymedso’s mission is to provide safe and effective care while treating all patient respiratory conditions. Its unique technology stands apart from traditional pulmonary physiotherapy techniques, as it is designed to be used non-invasively on patients of all ages, including those who require the most critical care.